Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques

被引：0
作者：
Laura Solforosi
Lea M. M. Costes
Jeroen T. B. M. Tolboom
Katherine McMahan
Tochi Anioke
David Hope
Tetyana Murdza
Michaela Sciacca
Emily Bouffard
Julia Barrett
Cindy Wu
Nicole Hachmann
Jessica Miller
Jingyou Yu
Xuan He
Catherine Jacob-Dolan
Sietske K. Rosendahl Huber
Liesbeth Dekking
Ronnie Chamanza
Ying Choi
Karin Feddes-de Boer
Dan H. Barouch
Hanneke Schuitemaker
Roland C. Zahn
Frank Wegmann
机构：
[1] Janssen Vaccines and Prevention B.V.,Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
[2] Harvard Medical School,Non
[3] Janssen Research and Development,Clinical Safety Toxicology/Pathology
[4] Ragon Institute of MGH,undefined
[5] MIT and Harvard,undefined
[6] Harvard Medical School,undefined
[7] Massachusetts Consortium on Pathogen Readiness,undefined
来源：
Nature Communications | / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Omicron spike (S) encoding vaccines as boosters, are a potential strategy to improve COVID-19 vaccine efficacy against Omicron. Here, macaques (mostly females) previously immunized with Ad26.COV2.S, are boosted with Ad26.COV2.S, Ad26.COV2.S.529 (encoding Omicron BA.1 S) or a 1:1 combination of both vaccines. All booster vaccinations elicit a rapid antibody titers increase against WA1/2020 and Omicron S. Omicron BA.1 and BA.2 antibody responses are most effectively boosted by vaccines including Ad26.COV2.S.529. Independent of vaccine used, mostly WA1/2020-reactive or WA1/2020-Omicron BA.1 cross-reactive B cells are detected. Ad26.COV2.S.529 containing boosters provide only slightly higher protection of the lower respiratory tract against Omicron BA.1 challenge compared with Ad26.COV2.S-only booster. Antibodies and cellular immune responses are identified as complementary correlates of protection. Overall, a booster with an Omicron-spike based vaccine provide only moderately improved immune responses and protection compared with the original Wuhan-Hu-1-spike based vaccine, which still provide robust immune responses and protection against Omicron.
引用
收藏
相关论文
共 62 条
[1]  
Wu K(2021)Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine N. Engl. J. Med. 384 1468-1470
[2]  
Liu Y(2021)Neutralizing Activity of BNT162b2-Elicited Serum N. Engl. J. Med. 384 1466-1468
[3]  
Alter G(2021)Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans Nature 596 268-272
[4]  
Viana R(2022)Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Nature 603 679-686
[5]  
Korber B(2020)Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus Cell 182 812-827.e19
[6]  
Davies NG(2021)Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Sci. (80-.) 372 0-10
[7]  
Vaughan A(2021)Omicron emerges N. Sci. 252 7-602
[8]  
Cao Y(2022)BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection Nature 608 593-24
[9]  
Shaheen N(2022)Could the new BA.2.75 sub-variant lead to another COVID-19 wave in the world? – Correspondence Int. J. Surg. 105 106861-10
[10]  
Premkumar L(2021)Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States View most current version A Context 2022 1-456.e11
1234567